Axonics® to Report 2019 Second Quarter and Six-Month Financial Results and Host a Conference Call on August 5

IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the second quarter and first six months of 2019, and provide an update on operations and FDA regulatory status after the market closes on Monday, August 5, 2019.

In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and current business developments.

Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 6687965.

A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company’s website at A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics System is the first rechargeable sacral neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain full-body MRI conditional labeling in Europe. Premarket approval for the System is currently pending with the U.S. FDA. For more information, visit the Company’s website at


Axonics’ Contact

Axonics Modulation Technologies, Inc.

Dan Dearen, +1-949-396-6320

President & Chief Financial Officer

Investor & Media Contact


Matt Clawson, +1-949-370-8500

error: Content is protected !!